Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Open Label Study for the Use of Tyrosine Kinase Inhibitors for Treatment of Cognitive Decline Due to Degenerative Dementias

Next Previous
X
Search
Trial Profile

Open Label Study for the Use of Tyrosine Kinase Inhibitors for Treatment of Cognitive Decline Due to Degenerative Dementias

Status: Recruiting
Phase of Trial: Phase I

Latest Information Update: 30 Sep 2022

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Bosutinib (Primary)
  • Indications Dementia; Mild cognitive impairment
  • Focus Adverse reactions

    • Most Recent Events

    • 25 Feb 2021 Planned number of patients changed from 20 to 150.
    • 25 Feb 2021 Planned End Date changed from 1 Dec 2021 to 31 Dec 2025.
    • 25 Feb 2021 Planned primary completion date changed from 1 Dec 2021 to 31 Dec 2023.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top